Literature DB >> 11991999

Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity.

Andrei N Varnavski1, Yi Zhang, Michael Schnell, John Tazelaar, Jean-Pierre Louboutin, Qian-Chun Yu, Adam Bagg, Guang-ping Gao, James M Wilson.   

Abstract

In an earlier study we evaluated innate immune responses to a first-generation adenoviral vector infused into the portal vein of rhesus monkeys who had never been exposed to adenovirus previously. In these animals, the systemic administration of E1/E3-deleted adenoviral vectors resulted in immediate activation of innate immunity and serious toxicity caused by targeting of vector to antigen-presenting cells and systemic inflammation. We analyze here how these responses are affected by vector-specific preexisting immunity that was induced by intramuscular immunization 6 months prior to evaluation. Our results show that preexposure to the vector substantially diminishes the transgene expression in most tissues but has little effect on gene transfer. Significantly, preimmunization does not eliminate systemic vector-induced toxicity. These conclusions are based on the presence of clinical features of coagulopathy and elevated levels of proinflammatory cytokine interleukin-6 in the serum of animals treated with vector after intramuscular immunization. Furthermore, preexisting immunity appears to induce a vector-specific inhibitory effect on erythroid progenitor development in the bone marrow that is not found when naive animals are challenged with vector.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11991999      PMCID: PMC137042          DOI: 10.1128/jvi.76.11.5711-5719.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells.

Authors:  L J Zhou; T F Tedder
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

2.  Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration.

Authors:  S Worgall; G Wolff; E Falck-Pedersen; R G Crystal
Journal:  Hum Gene Ther       Date:  1997-01-01       Impact factor: 5.695

3.  Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle.

Authors:  Y Yang; S E Haecker; Q Su; J M Wilson
Journal:  Hum Mol Genet       Date:  1996-11       Impact factor: 6.150

4.  Immediate inflammatory responses to adenovirus-mediated gene transfer in rat salivary glands.

Authors:  M R Adesanya; R S Redman; B J Baum; B C O'Connell
Journal:  Hum Gene Ther       Date:  1996-06-10       Impact factor: 5.695

5.  Adenovirus-mediated hepatic gene transfer in mice: comparison of intravascular and biliary administration.

Authors:  M J Peeters; G A Patijn; A Lieber; L Meuse; M A Kay
Journal:  Hum Gene Ther       Date:  1996-09-10       Impact factor: 5.695

6.  Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors.

Authors:  A Sarukhan; S Camugli; B Gjata; H von Boehmer; O Danos; K Jooss
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

7.  Circumventing the immune response to adenovirus-mediated gene therapy.

Authors:  A Kass-Eisler; L Leinwand; J Gall; B Bloom; E Falck-Pedersen
Journal:  Gene Ther       Date:  1996-02       Impact factor: 5.250

8.  Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype.

Authors:  C A Mack; W R Song; H Carpenter; T J Wickham; I Kovesdi; B G Harvey; C J Magovern; O W Isom; T Rosengart; E Falck-Pedersen; N R Hackett; R G Crystal; A Mastrangeli
Journal:  Hum Gene Ther       Date:  1997-01-01       Impact factor: 5.695

9.  Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy.

Authors:  G P Gao; Y Yang; J M Wilson
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

10.  Safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lungs of nonhuman primates.

Authors:  R W Wilmott; R S Amin; C R Perez; S E Wert; G Keller; G P Boivin; R Hirsch; J De Inocencio; P Lu; S F Reising; S Yei; J A Whitsett; B C Trapnell
Journal:  Hum Gene Ther       Date:  1996-02-10       Impact factor: 5.695

View more
  32 in total

1.  Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity.

Authors:  Ronald Vogels; David Zuijdgeest; Richard van Rijnsoever; Eric Hartkoorn; Irma Damen; Marie-Pierre de Béthune; Stefan Kostense; Germaine Penders; Niels Helmus; Wouter Koudstaal; Marco Cecchini; Antoinette Wetterwald; Mieke Sprangers; Angelique Lemckert; Olga Ophorst; Björn Koel; Michelle van Meerendonk; Paul Quax; Laura Panitti; Jos Grimbergen; Abraham Bout; Jaap Goudsmit; Menzo Havenga
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

2.  Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors.

Authors:  Dmitry M Shayakhmetov; Zong-Yi Li; Shaoheng Ni; André Lieber
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 3.  Innate immunity to adenovirus: lessons from mice.

Authors:  Svetlana Atasheva; Jia Yao; Dmitry M Shayakhmetov
Journal:  FEBS Lett       Date:  2019-12-08       Impact factor: 4.124

Review 4.  Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications.

Authors:  Zachary C Hartman; Daniel M Appledorn; Andrea Amalfitano
Journal:  Virus Res       Date:  2007-11-26       Impact factor: 3.303

Review 5.  Helper-dependent adenoviral vectors for liver-directed gene therapy.

Authors:  Nicola Brunetti-Pierri; Philip Ng
Journal:  Hum Mol Genet       Date:  2011-04-05       Impact factor: 6.150

6.  Development and assessment of human adenovirus type 11 as a gene transfer vector.

Authors:  Daniel Stone; Shaoheng Ni; Zong-Yi Li; Anuj Gaggar; Nelson DiPaolo; Qinghua Feng; Volker Sandig; André Lieber
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

7.  Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters.

Authors:  Debanjan Dhar; Jacqueline F Spencer; Karoly Toth; William S M Wold
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

8.  Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model.

Authors:  Debanjan Dhar; Jacqueline F Spencer; Karoly Toth; William S M Wold
Journal:  Mol Ther       Date:  2009-07-14       Impact factor: 11.454

9.  Efficient, long-term hepatic gene transfer using clinically relevant HDAd doses by balloon occlusion catheter delivery in nonhuman primates.

Authors:  Nicola Brunetti-Pierri; Gary E Stapleton; Mark Law; John Breinholt; Donna J Palmer; Yu Zuo; Nathan C Grove; Milton J Finegold; Karen Rice; Arthur L Beaudet; Charles E Mullins; Philip Ng
Journal:  Mol Ther       Date:  2008-12-02       Impact factor: 11.454

Review 10.  The influence of innate and pre-existing immunity on adenovirus therapy.

Authors:  Anne K Zaiss; Hidevaldo B Machado; Harvey R Herschman
Journal:  J Cell Biochem       Date:  2009-11-01       Impact factor: 4.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.